An immunohistochemical perspective of PPARβ and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours

British Journal of Cancer

Volumn 98, Issue 8, 2008, Pages 1415-1424

  Ahmed, N ^a,b,c   Riley, C ^a   Quinn, M A ^a,b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Differentiation; Metastasis; Ovarian carcinoma; Peroxisome proliferating activated receptor; Phosphoinositide dependent protein kinase 1

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER GRADING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; CAVEOLIN 1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; PPAR-BETA; PROTEIN-SERINE-THREONINE KINASES;

EID: 42149091578     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604306     Document Type: Article

References (71)

1. Ahmed N, Oliva K, Rice GE, Quinn MA (2004) Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. Clin Cancer Res 10: 2415-2420
2. Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, Agrez MV, Mok S, Baker MS (2002a) Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 23: 237-244
3. Ahmed N, Riley C, Oliva K, Rice G, Quinn M (2005) Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer 92: 1475-1485
4. Ahmed N, Riley C, Oliva K, Stutt E, Rice GE, Quinn MA (2003) Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J Pathol 201: 229-237
5. Ahmed N, Riley C, Rice GE, Quinn MA, Baker MS (2002b) Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J Histochem Cytochem 50: 1371-1380
6. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261-269
7. Alessi DR, Kozlowski MT, Weng QP, Morrice N, Avruch J (1998) 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 8: 69-81
8. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ (2003) Overexpression of AKT2/ protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63: 196-206
9. Aung CS, Faddy HM, Lister EJ, Monteith GR, Roberts-Thomson SJ (2006) Isoform specific changes in PPAR alpha and beta in colon and breast cancer with differentiation. Biochem Biophys Res Commun 340: 656-660
10. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99: 303-308
11. Bastie C, Holst D, Gaillard D, Jehl-Pietri C, Grimaldi PA (1999) Expression of peroxisome proliferator-activated receptor PPARdelta promotes induction of PPARgamma and adipocyte differentiation in 3T3C2 fibroblasts. J Biol Chem 274: 21920- 21925
12. Bastie C, Luquet S, Holst D, Jehl-Pietri C, Grimaldi PA (2000) Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation. J Biol Chem 275: 38768-38773
13. Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR (2005) Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(±) mice. Curr Biol 15: 1839-1846
14. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM (2006) The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal 18: 9-20
15. Daikoku T, Tranguch S, Chakrabarty A, Wang D, Khabele D, Orsulic S, Morrow JD, Dubois RN, Dey SK (2007) Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res 67: 5285- 5292
16. Dimova I, Raitcheva S, Dimitrov R, Doganov N, Toncheva D (2006) Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours. Eur J Cancer 42: 674 -679
17. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11: 63-70
18. Di-Poi N, Michalik L, Tan NS, Desvergne B, Wahli W (2003) The antiapoptotic role of PPARbeta contributes to efficient skin wound healing. J Steroid Biochem Mol Biol 85: 257 -265
19. Di-Poi N, Ng CY, Tan NS, Yang Z, Hemmings BA, Desvergne B, Michalik L, Wahli W (2005) Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor beta/delta during hair follicle development. Mol Cell Biol 25: 1696-1712
20. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10: 721-733
21. Dutil EM, Toker A, Newton AC (1998) Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). Curr Biol 8: 1366-1375
22. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45: 120-159
23. Feldman RI, Wu JM, Polokoff mA, Kochanny MJ, Dinter H, Zhu D, Biroc SL, Alicke B, Bryant J, Yuan S, Buckman BO, Lentz D, Ferrer M, Whitlow M, Adler M, Finster S, Chang Z, Arnaiz DO (2005) Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 280: 19867- 19874
24. Flynn P, Mellor H, Casamassima A, Parker PJ (2000a) Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide- dependent protein kinase. J Biol Chem 275: 11064-11070
25. Flynn P, Wongdagger M, Zavar M, Dean NM, Stokoe D (2000b) Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr Biol 10: 1439- 1442
26. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193- 204
27. Froment P, Gizard F, Defever D, Staels B, Dupont J, Monget P (2006) Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J Endocrinol 189: 199-209
28. Glinghammar B, Skogsberg J, Hamsten A, Ehrenborg E (2003) PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 308: 361-368
29. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10: 245-247
30. Han S, Ritzenthaler JD, Wingerd B, Roman J (2005) Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta. J Biol Chem 280: 33240-33249
31. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM (2004) Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 10: 481-483
32. Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De Jong J, Heirman C, Quartier E, Schuit F, Wahli W, Geerts A (2003) Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124: 184-201
33. Isonishi S, Ohkawa K, Tanaka T, Howell SB (2000) Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Br J Cancer 82: 34-38
34. Jaeckel EC, Raja S, Tan J, Das SK, Dey SK, Girod DA, Tsue TT, Sanford TR (2001) Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 127: 1253-1259
35. Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM (2004) Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 279: 23719-23727
36. King CC, Gardiner EM, Zenke FT, Bohl BP, Newton AC, Hemmings BA, Bokoch GM (2000) p21-Activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1). J Biol Chem 275: 41201- 41209
37. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ (1998) Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281: 2042-2045
38. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM (2006) Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res 66: 4394-4401
39. Masanek U, Stammler G, Volm M (2002) Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol 2: 37-41
40. Michalik L, Desvergne B, Wahli W (2003) Peroxisome proliferator-activated receptors beta/delta: emerging roles for a previously neglected third family member. Curr Opin Lipidol 14: 129-135
41. Michalik L, Desvergne B, Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4: 61-70
42. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317: 239- 242
43. Nahle Z (2004) PPAR trilogy from metabolism to cancer. Curr Opin Clin Nutr Metab Care 7: 397-402
44. Notterman DA, Alon U, Sierk AJ, Levine AJ (2001) Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 61: 3124-3130
45. Park BH, Vogelstein B, Kinzler KW (2001a) Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 98: 2598-2603
46. Park BK, Zeng X, Glazer RI (2001b) Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res 61: 7647-7653
47. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor beta(delta). Mol Cell Biol 20: 5119-5128
48. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC, Vazquez-Carrera M (2005) Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 65: 832-841
49. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, Thomas G (1998) Phosphorylation and activation of p70s6k by PDK1. Science 279: 707-710
50. Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Winton DJ, Peters JM, Clarke AR (2004) PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23: 8992-8996
51. Roymans D, Slegers H (2001) Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem 268: 487-498
52. Saluja I, Granneman JG, Skoff RP (2001) PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 33: 191-204
53. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E (2007) c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67: 1670-1679
54. Shao J, Sheng H, DuBois RN (2002) Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 62: 3282-3288
55. Shi Y, Hon M, Evans RM (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 99: 2613-2618
56. Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19: 7-15
57. Somasiri A, Howarth A, Goswami D, Dedhar S, Roskelley CD (2001) Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J Cell Sci 114: 1125-1136
58. Stadlmann S, Gueth U, Reiser U, Diener PA, Zeimet AG, Wight E, Mirlacher M, Sauter G, Mihatsch MJ, Singer G (2006) Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 19: 607-610
59. Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, Qiao R, Liu X, Wu H (2002) Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol 22: 3842-3851
60. Tan NS, Michalik L, Desvergne B, Wahli W (2003) Peroxisome proliferator-activated receptor (PPAR)-beta as a target for wound healing drugs: what is possible? Am J Clin Dermatol 4: 523 -530
61. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, Fluhmann B, Desvergne B, Wahli W (2001) Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15: 3263-3277
62. Toker A, Newton AC (2000) Cellular signaling: pivoting around PDK-1. Cell 103: 185 -188
63. Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN, Dey SK (2000) Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2: 483- 490
64. Vanhaesebroeck B, Alessi DR (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346(Pt 3): 561-576
65. Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH, Pinto I, Smith SA, Suckling KE, Wolf CR, Palmer CN (2001) The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 276: 44258-44265
66. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schafer R, Sers C (2001) Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159: 1635-1643
67. Xie Z, Yuan H, Yin Y, Zeng X, Bai R, Glazer RI (2006) 3-Phosphoinositide-dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer 6: 77
68. Xie Z, Zeng X, Waldman T, Glazer RI (2003) Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. Cancer Res 63: 5370-5375
69. Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopelovich L, Glazer RI (2005) Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 65: 3950-3957
70. Zeng X, Xu H, Glazer RI (2002) Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res 62: 3538-3543
71. Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE (2005) Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer 92: 113-119